Barclays
KRSA

Barclays’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Barclays’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-12
Closed -$295 – 5467
2026
Q2 		$295 Buy
+12
New +$273 ﹤0.01% 5067
2025
Q4 		– Sell
-1
Closed -$12 – 5327
2025
Q3 		$12 Buy
+1
New +$19 ﹤0.01% 5386
2021
Q4 		– Sell
-16
Closed -$7K – 4210
2021
Q3 		$7K Sell
16
-16
-50% -$7.33K ﹤0.01% 4564
2021
Q2 		$17K Sell
32
-100
-76% -$43.8K ﹤0.01% 4529
2021
Q1 		$52K Buy
132
+81
+159% +$42.6K ﹤0.01% 4189
2020
Q4 		$22K Sell
51
-22
-30% -$10.5K ﹤0.01% 4657
2020
Q3 		$62K Sell
73
-21
-22% -$16.8K ﹤0.01% 4491
2020
Q2 		$77K Buy
94
+38
+68% +$22.2K ﹤0.01% 4686
2020
Q1 		$20K Sell
56
-113
-67% -$56.4K ﹤0.01% 5641
2019
Q4 		$64K Buy
169
+85
+101% +$55.6K ﹤0.01% 5665
2019
Q3 		$143K Sell
84
-25
-23% -$37.8K ﹤0.01% 5199
2019
Q2 		$174K Buy
+109
New +$216K ﹤0.01% 5242

Other funds holding KRSA

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Activest Wealth Management
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Barclays's KRSA Position: Q3 2026 in Review

Barclays sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q3 2026, closing a stake of 12 shares — an estimated $295 sold.

Barclays first reported a position in KRSA in Q2 2019 and held it in 12 quarters. The position peaked at $174K in Q2 2019. 5 funds tracked by Wall St. Rank hold KRSA as of Q3 2026.

  • Barclays reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 12 Korsana Biosciences, Inc. Common Stock shares in Q3 2026, an estimated $295.
  • Barclays first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Barclays's Korsana Biosciences, Inc. Common Stock position peaked at $174K in Q2 2019.
  • 5 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.